{"id":408556,"date":"2021-01-05T08:43:21","date_gmt":"2021-01-05T13:43:21","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408556"},"modified":"2021-01-05T08:43:21","modified_gmt":"2021-01-05T13:43:21","slug":"medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/","title":{"rendered":"Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MARTINSRIED, Germany and MUNICH, Germany, Jan.  05, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xv8XNLvhSp0BwCgaj6u6DbDgNty9vB0ozEOzB9JVcCx-5x_dgm1eknjm0qEUcTFdqhrSP5Jw9YyvpDDxO0eVmg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Medigene AG<\/a> (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announced today that Prof. Dr. Dolores J. Schendel, Chief Executive Officer and Chief Scientific Officer of Medigene, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event, on Wednesday, 6 January 2021 from 8:00 am EST.<\/p>\n<p align=\"left\">The panel, entitled \u201cChallenges and Opportunities in Cell Therapy\u201d, will explore the potential of next generations of cell therapy to respond to current hurdles and challenges and how these will be positioned in the current treatment paradigm. Investors can pre-register for the panel discussion <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l9UUCVUp1KqHU-tLENkzsvYJRo9Mc6_ZXrOh5K1lrDIMMccb3eJzq7Vq4Tms601jieU6z8wnu9XyM7hJEcc9vVa9ovJl9ACtvcKQzXRarj4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a>.<\/p>\n<p align=\"left\">\n        <strong>About Medigene<\/strong>\n      <\/p>\n<p align=\"left\">Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.<\/p>\n<p align=\"left\">For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vao4jgXzXzOqCrpxEQo22wBk8QjrvGs06dJYpSXtoWxBt4WunrFcDnv9dFBOpaThurzDShLxPpW6X3BcTyYmCg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.medigene.com<\/a><\/p>\n<p align=\"left\">\n        <em>This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene<\/em><br \/>\n        <sup><br \/>\n          <em>\u00ae<\/em><br \/>\n        <\/sup><br \/>\n        <em>is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.<\/em>\n      <\/p>\n<p align=\"left\">\n        <strong>Medigene<\/strong><br \/>\n        <br \/>Dr. Gary Waanders, Dr. Anna Niedl<br \/>Phone: +49 89 2000 3333 01<br \/>e-mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jNGT6j57M70hCV9X8oSO6VKFzUOCOPBrxDqAxusJAsT9s1Rhd04OOnn64cinkD2TXlUHBQamnLkUiEpqBRuBwOTIH_b57mD5oqF6oPmS0lw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investor@medigene.com<\/a><\/p>\n<p align=\"left\">\n        <strong>LifeSci Advisors<\/strong><br \/>\n        <br \/>Mary-Ann Chang<br \/>Phone: +44 7483 284 853<br \/>e-mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rlAhWuYYuFjABf9nFcRB9s1yAdt5aj455KkWxAxPA8Im_sK-u3r782m0cU0xZTeX3rV0ewHvDYVRDmeYHawt2-4aORI7Z7QU9BcKM1WT2ITVzmneuYHvxEmC4CSxOt38\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mchang@lifesciadvisors.com<\/a><\/p>\n<p align=\"left\">In case you no longer wish to receive any information about Medigene, please inform us by e-mail (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jNGT6j57M70hCV9X8oSO6VKFzUOCOPBrxDqAxusJAsSzbb5KwuFHwXRejDpRipTOahETNeFcX33NoEAXtBd_rxJFjO9SssIZl05-vo20aks=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investor@medigene.com<\/a>). We will then delete your address from our distribution list.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDc5NSMzOTA1MTYyIzUwMDA3MDA4MQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/1ff55e89-2d12-4023-9219-1a24e4661e5d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MARTINSRIED, Germany and MUNICH, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announced today that Prof. Dr. Dolores J. Schendel, Chief Executive Officer and Chief Scientific Officer of Medigene, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event, on Wednesday, 6 January 2021 from 8:00 am EST. The panel, entitled \u201cChallenges and Opportunities in Cell Therapy\u201d, will explore the potential of next generations of cell therapy to respond to current hurdles and challenges and how these will be positioned in the current treatment paradigm. Investors can pre-register for the panel discussion here. About Medigene &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408556","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MARTINSRIED, Germany and MUNICH, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announced today that Prof. Dr. Dolores J. Schendel, Chief Executive Officer and Chief Scientific Officer of Medigene, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event, on Wednesday, 6 January 2021 from 8:00 am EST. The panel, entitled \u201cChallenges and Opportunities in Cell Therapy\u201d, will explore the potential of next generations of cell therapy to respond to current hurdles and challenges and how these will be positioned in the current treatment paradigm. Investors can pre-register for the panel discussion here. About Medigene &hellip; Continue reading &quot;Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T13:43:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDc5NSMzOTA1MTYyIzUwMDA3MDA4MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event\",\"datePublished\":\"2021-01-05T13:43:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\\\/\"},\"wordCount\":310,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDc5NSMzOTA1MTYyIzUwMDA3MDA4MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\\\/\",\"name\":\"Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDc5NSMzOTA1MTYyIzUwMDA3MDA4MQ==\",\"datePublished\":\"2021-01-05T13:43:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDc5NSMzOTA1MTYyIzUwMDA3MDA4MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDc5NSMzOTA1MTYyIzUwMDA3MDA4MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/","og_locale":"en_US","og_type":"article","og_title":"Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event - Market Newsdesk","og_description":"MARTINSRIED, Germany and MUNICH, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announced today that Prof. Dr. Dolores J. Schendel, Chief Executive Officer and Chief Scientific Officer of Medigene, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event, on Wednesday, 6 January 2021 from 8:00 am EST. The panel, entitled \u201cChallenges and Opportunities in Cell Therapy\u201d, will explore the potential of next generations of cell therapy to respond to current hurdles and challenges and how these will be positioned in the current treatment paradigm. Investors can pre-register for the panel discussion here. About Medigene &hellip; Continue reading \"Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T13:43:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDc5NSMzOTA1MTYyIzUwMDA3MDA4MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event","datePublished":"2021-01-05T13:43:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/"},"wordCount":310,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDc5NSMzOTA1MTYyIzUwMDA3MDA4MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/","name":"Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDc5NSMzOTA1MTYyIzUwMDA3MDA4MQ==","datePublished":"2021-01-05T13:43:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDc5NSMzOTA1MTYyIzUwMDA3MDA4MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDc5NSMzOTA1MTYyIzUwMDA3MDA4MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigene-to-take-part-in-cell-therapy-panel-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408556"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408556\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408556"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408556"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}